|
Match
|
Document |
Document Title |
|
|
US20120015939 |
TOPICAL TREATMENT OF NEUROPATHIC PAIN AND METHODS OF DIAGNOSIS
Alpha-2 adrenergic agonists such as clonidine may be used to treat the pain associated with painful diabetic neuropathy (PDN) only in a subset of these patients. Targeted nociceptors (pain fibers)...
|
|
|
US20110065661 |
PHARMACOPERONES FOR CORRECTING DISEASE STATES INVOLVING PROTEIN MISFOLDING
This application relates to methods of identifying pharmacoperone agents that can restore function to a misfolded protein, such as a misfolded protein that causes disease. Also disclosed are...
|
|
|
US20110263601 |
METHODS OF TREATING ULCERATIVE COLITIS
Methods are disclosed for treating ulcerative colitis and related diseases and disorders, which comprise inhibiting tryptophan hydroxylase (TPH) in patients in need thereof.
|
|
|
US20120064181 |
P2X3 Receptor Antagonists for Treatment of Pain
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or...
|
|
|
US20110206783 |
P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or...
|
|
|
US20110003822 |
P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or...
|
|
|
US20110098312 |
METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS
Method and compositions for delaying the onset or progression of retinopathy, including administering at least one neuronal nicotinic ligand are disclosed.
|
|
|
US20110178079 |
GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS
Novel guanidine compounds having the formula in which R1, R2, and R4 are as defined, are effective as sodium channel dockers in neuronal mammalian cells and as anesthetics and/or analgesics,...
|
|
|
US20100310680 |
COMPOSITION AND METHOD FOR TREATING ACNE
This invention relates to a novel composition and method useful for the treatment of acne, and more particularly, to a composition and method for reducing an appearance of post acne marks and scars...
|
|
|
US20100317664 |
METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN
Methods and compounds are disclosed for affecting gastrointestinal motility and gastric emptying, which comprise inhibiting tryptophan hydroxylase (TPH) in patients in need thereof
|
|
|
US20110301125 |
Method for Treating Macular Degeneration
Provided herein are novel and useful methods for preventing, treating, or ameliorating a macular degeneration such as dry macular degeneration, wet macular degeneration and age related macular...
|
|
|
US20120121540 |
Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).
|
|
|
US20120040991 |
3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS
Disclosed are 3-azabicyclo[4.1.0]heptane derivatives of formula (I) and their use as orexin receptor antagonists.
|
|
|
US20110118282 |
Soluble Guanylate Cyclase Activators
A compound having the structure useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris,...
|
|
|
US20110288022 |
TREATMENT OF DEPRESSIVE DISORDERS
The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and...
|
|
|
US20120058939 |
AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF
Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and...
|
|
|
US20110003737 |
AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF
Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and...
|
|
|
US20110190285 |
METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT
The present invention provides methods of treating a botulinum toxin related condition in a subject. In certain embodiments, the methods involve administering a compound of the following formulas:...
|
|
|
US20120053177 |
COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
|
|
|
US20110152213 |
RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES
It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the...
|
|
|
US20110105448 |
Stable Topical Formulation Comprising Voriconazole
The present invention relates to a stable topical formulation comprising an effective amount of voriconazole or its pharmaceutically acceptable salt, and at least a pharmaceutical carrier; a...
|
|
|
US20110294761 |
STEM CELL CULTURES
The present invention relates compounds for stabilizing cells and methods of their use.
|
|
|
US20110224233 |
STEM CELL CULTURES
The present invention relates compounds for stabilizing cells and methods of their use.
|
|
|
US20100331312 |
MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
Amide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3 receptor. Compounds of the present invention and pharmaceutical compositions...
|
|
|
US20110263600 |
Method for preventing or treating a disease related to the glucocorticoid receptor
A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-dihydroquinoline compound or a...
|
|
|
US20110092500 |
SGC STIMULATORS, SGC ACTIVATORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF HEARING IMPAIRMENT
The invention provides pharmacological compositions comprising a stimulator or activator of the soluble guanylate cyclase (sGC) either alone or in combination for the treatment of hearing...
|
|
|
US20110009831 |
ANTIMICROBIAL COATING FOR DERMALLY INVASIVE DEVICES
An antimicrobial coating applied to a transdermal surface of a catheter device. An antimicrobial coating applied to catheter device such that when the catheter device is fully inserted, the...
|
|
|
US20120107308 |
GENE EXPRESSION LEVELS OF EGFR, VEGFR2, AND ERCC1 ASSOCIATED WITH CLINICAL OUTCOMES OF CHEMOTHERAPY
The invention provides compositions and methods for identifying a cancer patient suitable for anti-VEGF therapy. After determining if a patient is likely to be successfully treated, the invention...
|
|
|
US20110245272 |
PYRIDO[4,3-B]INDOLES AND METHODS OF USE
This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions...
|
|
|
US20110144096 |
TREATING VARIOUS DISORDERS USING TRKB AGONISTS
Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four...
|
|
|
US20100190705 |
Suppression of glial fibrillary acidic protein
Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell....
|
|
|
US20110059154 |
CCR5 ANTAGONISTS AS PROPHYLACTICS FOR PREVENTING HIV INFECTION AND METHODS OF INHIBITING TRANSMISSION OF SAME
Topical cream, ointment, lotion, gel, foam formulations and slow release formulations or devices are provided including certain CCR5 antagonists as prophylactics for the prevention, retardation or...
|
|
|
US20110230485 |
6-PHENYL-PYRIMIDIN-4-YL-(PHENYLAMINE OR PHENOXY) DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
This invention relates to novel 6-phenyl-phymidin-4-yl-(phenylannine or phenoxy) derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological...
|
|
|
US20110152293 |
ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF
Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare...
|
|
|
US20110318393 |
Substituted Pyrazole Compounds
Provided are substituted pyrazole compounds which are useful as protein kinase inhibitors, compositions comprising the compounds, and methods of use thereof. The protein kinase inhibitors are...
|
|
|
US20100324038 |
TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER
The invention relates to compounds of formula I, wherein Ra is —C(O)OR1, in which R1 is 1-7C-alkyl, 3-7C-cycloalkyl, or 1-7C-alkyl substituted by one to four substituents independently selected f...
|
|
|
US20110263617 |
Combination therapy for the treatment of diabetes and related conditions
The present invention relates to combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly...
|
|
|
US20110092517 |
Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases
Provided herein are methods for treatment, prevention, or amelioration of one or more symptoms of a disease or condition related to disorders of insulin and/or glucose metabolism, inflammatory...
|
|
|
US20120101101 |
THERAPEUTIC AGENT FOR MOTOR DISORDERS
Provided are an agent for the treatment and/or prophylaxis of a movement disorder, the agent for the treatment and/or prophylaxis wherein the movement disorder is extrapyramidal syndrome, the agent...
|
|
|
US20120122885 |
PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE
Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
|
|
|
US20110288102 |
IL-8 BIOMARKER FOR MONITORING CANCER TREATMENT
The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.
|
|
|
US20110183988 |
COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds...
|
|
|
US20110245222 |
Methods for Using Carboxamide, Sulfonamide and Amine Compounds
Disclosed are uses of carboxamide, sulfonamide and amine compounds for the treatment and amelioration of disorders and conditions related to oxidative stress, mitochondrial dysfunction, free...
|
|
|
US20090176762 |
JNK Inhibitors for Treatment of Skin Diseases
This invention relates to the use of a JNK inhibitor for treating and/or preventing skin diseases selected from psoriasis and dermatitis.
|
|
|
US20100331330 |
METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC STROKE
A method of treating a cerebrovascular accident in a subject includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof to the subject after ...
|
|
|
US20100298345 |
SYNTHETIC COMPOUNDS AND DERIVATIVES AS MODULATORS OF SMOKING OR NICOTINE INGESTION AND LUNG CANCER
Disclosed are nicotine-related compounds that selectively inhibit cytochrome P-450 2A6 (CYP2A6), selectively inhibit cytochrome P-450 2A13 (CYP2A13), and/or selectively modulate a nicotinic...
|
|
|
US20120122852 |
TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE
The invention concerns tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit of general formula (I): Wherein A, P, Y, R1, R2 and R3 are as defined herein. The invention...
|
|
|
US20110189174 |
COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR INHIBITING PROGRESSION OF, PATHOGENIC OCULAR NEOVASCULARIZATION
A composition for treating, reducing, ameliorating, alleviating, or inhibiting the progression of, pathological ocular neovascularization comprises an integrin or vitronectin receptor antagonist...
|
|
|
US20110319429 |
SUBSTITUTED 1,1,3,1-TETRAOXIDOBENZO[D][1,3,2]DITHIAZOLES AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
Compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) and methods of using the compounds.
|
|
|
US20120083502 |
HETEROCYCLIC COMPOUNDS AND THEIR USES
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders,...
|